UFPT Stock Analysis: Buy, Sell, or Hold?

UFPT - UFP Technologies Inc

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
$255.87
4.73 (1.88%) ▲
5d: +0.79%
30d: +15.24%
90d: +38.1%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Feb 24, 2026 20d

Get Alerted When UFPT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: UFPT shows positive signals but monitor for confirmation. Market pricing in 2.3% annual growth which appears achievable. Moderate conviction.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$330.27
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$205.07
Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.8x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: UFPT is currently trading at $255.87, which is considered slightly high relative to its 30-day fair value range of $237.92 to $261.68. The stock's valuation (Forward PE: 24.4) is in line with its historical norms (22.8). At these levels, the market is pricing in 2.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, UFPT is in a strong uptrend. Immediate support is located at $240.62, while resistance sits at $272.60.

Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $329.50 (+28.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Fair Price Range $237.92 - $261.68
Company Quality Score 56/100 (HOLD)
Options IV Signal 8th percentile (COMPLACENCY WARNING)
Volume Confirmation HIGH
Confidence Score 72.7%

All Signals

  • BULLISH: Options cheap (IV 8th percentile)
  • NEUTRAL: Mixed technical signals (55/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 28.8% below Wall St target ($329.50)
  • NEUTRAL: Market pricing in 2.3% annual earnings growth - fairly valued

Fair Price Analysis

30-Day Fair Range $237.92 - $261.68
Current vs Fair Value SLIGHTLY HIGH
Expected Move (7 Days) ±$13.43 (5.2%)

Support & Resistance Levels

Support Level $240.62
Resistance Level $272.60
Current Trend Strong Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 24.41
Wall Street Target $329.50 (+28.8%)
Revenue Growth (YoY) 6.5%
Profit Margin 11.2%
Valuation Premium vs History +2.3% premium
PE vs Historical 24.4 vs 22.8 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +2.3% (market-implied from PE analysis)
1-Year Target $261.76 (+2%)
2-Year Target $267.78 (+5%)
3-Year Target $273.93 (+7%)
3-Yr Target (if PE normalizes) (PE: 24→23) PE COMPRESSION $255.87 (0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 24.4, Growth: 9.4%) $334.69 (+31%)
Base: (SPY PE: 22.3, Growth: 9.4%) $305.77 (+20%)
Bear: (PE: 19.0, Growth: 9.4%) $259.90 (+2%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 28.67 | Current EPS (TTM): $8.76
Bull Case $330.58 (+29%)
Analyst growth 19.7%, PE expands to 31.5
Base Case $300.52 (+18%)
Market implied 19.7%, PE stable at 28.7
Bear Case $170.78 (-33%)
Severe decline -20.0%, PE contracts to 24.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 02, 2026 6:16 PM ET
Data refreshes hourly during market hours. Next update: 7:16 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
BSX
Boston Scientific Corp
STRONG BUY
34 analysts
$124 59 HOLD
SYK
Stryker Corporation
BUY
32 analysts
$424 69 BUY
MDT
Medtronic PLC
BUY
32 analysts
$111 66 BUY
PODD
Insulet Corporation
STRONG BUY
23 analysts
$370 57 HOLD
EW
Edwards Lifesciences Corp
HOLD
32 analysts
$97 57 HOLD

More Analysis for UFPT

UFPT Technical Chart UFPT Price Prediction UFPT Earnings Date UFPT Investment Advisor UFPT Fair Price Analyzer UFPT Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals